New Results
More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway
Jonathan J. Hodgins, John Abou-Hamad, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M. Park, Claire Fong-McMaster, Mathieu F. Crupi, John C. Bell, Mary-Ellen Harper, View ORCID ProfileBenjamin H. Rotstein, Rebecca C. Auer, Barbara C. Vanderhyden, Luc A. Sabourin, Marie-Claude Bourgeois-Daigneault, David P. Cook, Michele Ardolino
doi: https://doi.org/10.1101/2022.08.31.506095
Jonathan J. Hodgins
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
3Center for Infection, Immunity, and Inflammation, University of Ottawa
John Abou-Hamad
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
4Department of Cellular and Molecular Medicine, University of Ottawa
Ash Hagerman
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
3Center for Infection, Immunity, and Inflammation, University of Ottawa
Edward Yakubovich
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
4Department of Cellular and Molecular Medicine, University of Ottawa
Christiano Tanese de Souza
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
Marie Marotel
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
3Center for Infection, Immunity, and Inflammation, University of Ottawa
Ariel Buchler
5Department of Chemistry and Biomolecular Sciences, University of Ottawa
6University of Ottawa Heart Institute
Saleh Fadel
7The Ottawa Hospital
8Department of Pathology and Laboratory Medicine, University of Ottawa
Maria M. Park
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
3Center for Infection, Immunity, and Inflammation, University of Ottawa
Claire Fong-McMaster
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
9Ottawa Institute for Systems Biology
Mathieu F. Crupi
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
John C. Bell
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
Mary-Ellen Harper
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
3Center for Infection, Immunity, and Inflammation, University of Ottawa
9Ottawa Institute for Systems Biology
Benjamin H. Rotstein
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
5Department of Chemistry and Biomolecular Sciences, University of Ottawa
6University of Ottawa Heart Institute
Rebecca C. Auer
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
Barbara C. Vanderhyden
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
3Center for Infection, Immunity, and Inflammation, University of Ottawa
4Department of Cellular and Molecular Medicine, University of Ottawa
Luc A. Sabourin
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
4Department of Cellular and Molecular Medicine, University of Ottawa
Marie-Claude Bourgeois-Daigneault
10Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal
11“Centre Hospitalier de l’Université de Montréal” Research Centre, Cancer and Immunopathology axes
David P. Cook
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
4Department of Cellular and Molecular Medicine, University of Ottawa
Michele Ardolino
1Cancer Therapeutics Program, Ottawa Hospital Research Institute
2Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
3Center for Infection, Immunity, and Inflammation, University of Ottawa
Posted September 03, 2022.
More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway
Jonathan J. Hodgins, John Abou-Hamad, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M. Park, Claire Fong-McMaster, Mathieu F. Crupi, John C. Bell, Mary-Ellen Harper, Benjamin H. Rotstein, Rebecca C. Auer, Barbara C. Vanderhyden, Luc A. Sabourin, Marie-Claude Bourgeois-Daigneault, David P. Cook, Michele Ardolino
bioRxiv 2022.08.31.506095; doi: https://doi.org/10.1101/2022.08.31.506095
More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway
Jonathan J. Hodgins, John Abou-Hamad, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M. Park, Claire Fong-McMaster, Mathieu F. Crupi, John C. Bell, Mary-Ellen Harper, Benjamin H. Rotstein, Rebecca C. Auer, Barbara C. Vanderhyden, Luc A. Sabourin, Marie-Claude Bourgeois-Daigneault, David P. Cook, Michele Ardolino
bioRxiv 2022.08.31.506095; doi: https://doi.org/10.1101/2022.08.31.506095
Subject Area
Subject Areas
- Biochemistry (11730)
- Bioengineering (8743)
- Bioinformatics (29179)
- Biophysics (14964)
- Cancer Biology (12080)
- Cell Biology (17399)
- Clinical Trials (138)
- Developmental Biology (9417)
- Ecology (14174)
- Epidemiology (2067)
- Evolutionary Biology (18294)
- Genetics (12233)
- Genomics (16791)
- Immunology (11858)
- Microbiology (28051)
- Molecular Biology (11575)
- Neuroscience (60919)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4955)
- Plant Biology (10422)
- Synthetic Biology (2881)
- Systems Biology (7338)
- Zoology (1650)